Cargando…

Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches

BACKGROUND: The 3C-like proteases (3CL(pro)s) are cysteine-rich homodimeric proteins and can be covalently modified by numerous natural and synthetic compounds, which in turn, block the proteolytic activity or the formation of enzymatically active dimeric forms. Although herbal medicines have been w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ya-Ni, Zhu, Guang-Hao, Liu, Wei, Xiong, Yuan, Hu, Qing, Zhuang, Xiao-Yu, Jia, Gui-Hua, Zhang, Wei-Dong, Ge, Guang-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier GmbH. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052880/
https://www.ncbi.nlm.nih.gov/pubmed/37037086
http://dx.doi.org/10.1016/j.phymed.2023.154796
_version_ 1785015259627520000
author Zhang, Ya-Ni
Zhu, Guang-Hao
Liu, Wei
Xiong, Yuan
Hu, Qing
Zhuang, Xiao-Yu
Jia, Gui-Hua
Zhang, Wei-Dong
Ge, Guang-Bo
author_facet Zhang, Ya-Ni
Zhu, Guang-Hao
Liu, Wei
Xiong, Yuan
Hu, Qing
Zhuang, Xiao-Yu
Jia, Gui-Hua
Zhang, Wei-Dong
Ge, Guang-Bo
author_sort Zhang, Ya-Ni
collection PubMed
description BACKGROUND: The 3C-like proteases (3CL(pro)s) are cysteine-rich homodimeric proteins and can be covalently modified by numerous natural and synthetic compounds, which in turn, block the proteolytic activity or the formation of enzymatically active dimeric forms. Although herbal medicines have been widely used to treat COVID-19, identification of the key herbal constituents that can covalently modify the 3CL(pro)s in β-coronaviruses (CoVs) remains a big challenge. AIMS: To construct a comprehensive approach for efficient discovering the covalent SARS-CoV-2 3CL(pro) inhibitors from herbal medicines. To decipher the key anti-SARS-CoV-2 3CL(pro) constituents in Ginkgo biloba extract 50 (GBE50) and to study their anti-SARS-CoV-2 3CL(pro) mechanisms. METHODS: SARS-CoV-2 3CL(pro) inhibition assay including time-dependent inhibition assays and inactivation kinetic analyses were conducted using a fluorescence-based biochemical assay. The constituents in GBE50 were analyzed by UHPLC-Q-Exactive Orbitrap HRMS. The peptides modified by herbal constituents were characterized by using nanoLC-MS/MS. RESULTS: Following testing the anti-SARS-CoV-2 3CL(pro) effects of 104 herbal medicines, it was found that Ginkgo biloba extract 50 (GBE50) potently inhibited SARS-CoV-2 3CL(pro) in dose- and time-dependent manners. A total of 38 constituents were identified from GBE50 by UHPLC-Q-Exactive Orbitrap HRMS, while 26 peptides modified by 18 constituents were identified by chemoproteomic profiling. The anti-SARS-CoV-2 3CL(pro) effects of 18 identified covalent inhibitors were then validated by performing time-dependent inhibition assays. The results clearly demonstrated that most tested constituents showed time-dependent inhibition on SARS-CoV-2 3CL(pro), while gallocatechin and sciadopitysin displayed the most potent anti-SARS-CoV-2 3CL(pro) effects. CONCLUSION: Collectively, GBE50 and some constituents in this herbal product could strongly inhibit SARS-CoV-2 3CL(pro) in dose- and time-dependent manner. Gallocatechin and sciadopitysin were identified as potent SARS-CoV-2 3CL(pro) inhibitors, which offers promising lead compounds for the development of novel anti-SARS-CoV-2 drugs.
format Online
Article
Text
id pubmed-10052880
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier GmbH.
record_format MEDLINE/PubMed
spelling pubmed-100528802023-03-29 Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches Zhang, Ya-Ni Zhu, Guang-Hao Liu, Wei Xiong, Yuan Hu, Qing Zhuang, Xiao-Yu Jia, Gui-Hua Zhang, Wei-Dong Ge, Guang-Bo Phytomedicine Original Article BACKGROUND: The 3C-like proteases (3CL(pro)s) are cysteine-rich homodimeric proteins and can be covalently modified by numerous natural and synthetic compounds, which in turn, block the proteolytic activity or the formation of enzymatically active dimeric forms. Although herbal medicines have been widely used to treat COVID-19, identification of the key herbal constituents that can covalently modify the 3CL(pro)s in β-coronaviruses (CoVs) remains a big challenge. AIMS: To construct a comprehensive approach for efficient discovering the covalent SARS-CoV-2 3CL(pro) inhibitors from herbal medicines. To decipher the key anti-SARS-CoV-2 3CL(pro) constituents in Ginkgo biloba extract 50 (GBE50) and to study their anti-SARS-CoV-2 3CL(pro) mechanisms. METHODS: SARS-CoV-2 3CL(pro) inhibition assay including time-dependent inhibition assays and inactivation kinetic analyses were conducted using a fluorescence-based biochemical assay. The constituents in GBE50 were analyzed by UHPLC-Q-Exactive Orbitrap HRMS. The peptides modified by herbal constituents were characterized by using nanoLC-MS/MS. RESULTS: Following testing the anti-SARS-CoV-2 3CL(pro) effects of 104 herbal medicines, it was found that Ginkgo biloba extract 50 (GBE50) potently inhibited SARS-CoV-2 3CL(pro) in dose- and time-dependent manners. A total of 38 constituents were identified from GBE50 by UHPLC-Q-Exactive Orbitrap HRMS, while 26 peptides modified by 18 constituents were identified by chemoproteomic profiling. The anti-SARS-CoV-2 3CL(pro) effects of 18 identified covalent inhibitors were then validated by performing time-dependent inhibition assays. The results clearly demonstrated that most tested constituents showed time-dependent inhibition on SARS-CoV-2 3CL(pro), while gallocatechin and sciadopitysin displayed the most potent anti-SARS-CoV-2 3CL(pro) effects. CONCLUSION: Collectively, GBE50 and some constituents in this herbal product could strongly inhibit SARS-CoV-2 3CL(pro) in dose- and time-dependent manner. Gallocatechin and sciadopitysin were identified as potent SARS-CoV-2 3CL(pro) inhibitors, which offers promising lead compounds for the development of novel anti-SARS-CoV-2 drugs. Elsevier GmbH. 2023-06 2023-03-29 /pmc/articles/PMC10052880/ /pubmed/37037086 http://dx.doi.org/10.1016/j.phymed.2023.154796 Text en © 2023 Elsevier GmbH. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Zhang, Ya-Ni
Zhu, Guang-Hao
Liu, Wei
Xiong, Yuan
Hu, Qing
Zhuang, Xiao-Yu
Jia, Gui-Hua
Zhang, Wei-Dong
Ge, Guang-Bo
Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title_full Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title_fullStr Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title_full_unstemmed Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title_short Discovery and characterization of the covalent SARS-CoV-2 3CL(pro) inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
title_sort discovery and characterization of the covalent sars-cov-2 3cl(pro) inhibitors from ginkgo biloba extract via integrating chemoproteomic and biochemical approaches
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052880/
https://www.ncbi.nlm.nih.gov/pubmed/37037086
http://dx.doi.org/10.1016/j.phymed.2023.154796
work_keys_str_mv AT zhangyani discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT zhuguanghao discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT liuwei discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT xiongyuan discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT huqing discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT zhuangxiaoyu discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT jiaguihua discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT zhangweidong discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches
AT geguangbo discoveryandcharacterizationofthecovalentsarscov23clproinhibitorsfromginkgobilobaextractviaintegratingchemoproteomicandbiochemicalapproaches